No Data
No Data
Zhejiang Anglikang Pharmaceutical (002940.SZ): The main products of ChunDi in Jiangxi include plant-based vitamin D3, plant-based 25-hydroxy vitamin D3 and other series of products.
On August 8th, Gelunhui reported that Zhejiang Anglikang Pharmaceutical (002940.SZ) stated on the investor platform that its subsidiary Jiangxi Chundi's main products include plant-derived vitamin D3, plant-derived 25-hydroxy vitamin D3 and other products. The price of vitamins is affected by market supply and demand. Investors should pay attention to investment risks.
Anglikang Pharmaceutical Gets Nod to Register Lanthanum Carbonate Tablets
Zhejiang Anglikang Pharmaceutical (002940.SZ): Polycaprolactone calcium tablets have obtained pharmaceutical registration certificate.
Zhejiang Anglikang Pharmaceutical (002940.SZ) announced that it has recently received the approval of the National Medical Products Administration for Polycaprolactone Polyol (PCL) Injection, which is a solvent and polyethylene glycol-free long-acting sustained-release formulation for injection. PCL Injection is mainly used for the treatment of mild to moderate degenerative joint disease (DJD) in dogs.
Zhejiang Anglikang Pharmaceutical (002940.SZ): Cefaclor Capsule Passed the Consistency Evaluation of Generic Drugs.
On July 15th, Gelunhui reported that Zhejiang Anglikang Pharmaceutical (002940.SZ) has received the drug supplementary application approval notice for Cefradine capsules (0.125g, 0.25g) issued by the National Medical Products Administration. The pharmaceutical has passed the evaluation for consistency of quality and efficacy with generic drugs. Cefradine capsules are suitable for respiratory infections caused by sensitive bacteria, such as acute tonsillitis, pharyngitis, sinusitis, bronchitis, pneumonia, as well as otitis media, urinary tract infection and skin and soft tissue infections.
Zhejiang Anglikang Pharmaceutical (002940.SZ): Sacubitril Valsartan Sodium Tablets Obtains Drug Registration Certificate.
Zhejiang Anglikang Pharmaceutical (002940.SZ) announced on July 8th that it has recently received the Drug Registration Certificate for Sacubitril and Valsartan Sodium Tablets (200mg) issued by the National Medical Products Administration (NMPA). Sacubitril and Valsartan Sodium Tablets are drugs used to treat chronic heart failure and are used in adult patients with chronic heart failure with reduced ejection fraction and primary hypertension. The product is developed jointly by the company, Suzhou Pengxu Pharmaceutical Technology Co., Ltd. and Suzhou Jingyun Pharmaceutical Technology Co., Ltd.
Anglikang Pharmaceutical's Two Drugs Get Marketing Nod
No Data